LAS VEGAS, April 30, 2009 (GLOBE NEWSWIRE) -- In the small cap world, innovation and speed to market can be the difference between achieving revenue and a good idea that dies on the proverbial vine. For investors, the ability to identify a company exemplifying these attributes can be paramount.
A brief review of SenoRx Inc. (Nasdaq:SENO) reveals a company displaying the aforementioned virtues with a series of successes in its target market. The Irvine, California based medical device company develops, manufactures, and sells minimally invasive devices for the diagnosis and treatment of breast cancer and is a rapidly growing participant in the medical device market which includes Endologix, Inc. (Nasdaq:ELGX), Micrus Endovascular Corporation (Nasdaq:MEND), Vascular Solutions, Inc. (Nasdaq:VASC), VNUS(r) Medical Technologies, Inc. (Nasdaq:VNUS), and Volcano Corporation (Nasdaq:VOLC).
SenoRx has established a trend of continual product development and rapid penetration in the breast cancer arena, offering health care providers both diagnostic and therapeutic technologies to better detect and treat breast cancer, the second most frequently diagnosed cancer among women. Given the expanding category in which the company's product line is utilized, each additional product generates new revenue streams and increased aggregate market share for the SenoRx line.
SenoRx's first major success in women's oncology was EnCor (tm), the only "open/closed" tissue collection system, providing the operator with a clear view of tissue samples through a proprietary transparent collection chamber, and the ability to either open the chamber to examine and remove one or more samples, or to continue uninterrupted collection of multiple samples.
EnCor's successful introduction was followed by Contura (tm). The company received 510(k) clearance from the U.S. Food and Drug Administration on May 23, 2007 for Contura, its Multi-Lumen Radiation Balloon (MLB) catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. For appropriate patients, Contura MLB is one of a new class of devices which can reduce treatment time to five days from six to eight weeks. Contura was quickly commercialized in the United States and SenoRx has recently announced plans to commercialize the technology in Europe. Effectively launched in January 2008, sales of Contura steadily gained momentum throughout the year culminating in a 55% improvement sequentially in the fourth quarter versus the third quarter of 2008. Moreover, SenoRx has continued to enhance the efficacy of Contura with enhancements to its initial design.
The success in taking these technologies to the marketplace has been followed by other achievements that establish SenoRx as a brand recognized for innovation in both diagnostic and therapeutic applications. Using a sales force armed with the leverage of EnCor and Contura's market acceptance, SenoRx has added to its incremental revenue opportunities with the introduction and commercialization of other technologies in the breast cancer arena.
In addition to its growing product line for the diagnosis and treatment of breast cancer, SenoRx has recently announced the introduction of StarchMark, the company's newest addition to its line of biopsy site markers. As a market leader in breast biopsy markers, SenoRx possesses the widest array of advanced markers offering enhanced visualization in all three imaging modalities -- stereotactic, ultrasound and MRI. StarchMark is the first and only breast biopsy marker that uses polysaccharide (starch) pellets to help manage and control bleeding.
For an Integrity Media profile of SenoRx please visit: www.IntegrityIR.com/SENO
Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. Small Cap Sentinel is property of Integrity Media Inc. (IMI). IMI provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies haven't always approved the statements made in this report. This report is neither a solicitation to buy nor offer to sell securities and is for information purposes only and shouldn't be used as basis for investment decisions. IMI isn't an investment advisor, analyst or licensed broker dealer and this report isn't investment advice. IMI has been paid thirty-thousand dollars by SenoRx for this report and other services to be performed over the remainder of the calendar year. Paid reports constitute a conflict of interest as to IMI's ability to remain objective in communication regarding subject companies.